Article

Brachytherapy trial enrolling new patients

Buford, GA—Patients are being enrolled into a clinical trial to evaluate the safety and feasibility of the TheraSight Ocular Brachytherapy System for treatment of subfoveal choroidal neovascularization associated with wet age-related macular degeneration.

Buford, GA-Patients are being enrolled into a clinical trial to evaluate the safety and feasibility of the TheraSight Ocular Brachytherapy System for treatment of subfoveal choroidal neovascularization associated with wet age-related macular degeneration.

The one-time brachytherapy treatment, sponsored by Theragenics Corp., compares three doses of radiation with a group of 30 patients at six clinical sites.

Eligible patients for the pilot study must have a lesion size ≤6 mm greatest linear dimension, submacular blood <75% of the lesion, subretinal fibrosis <25% of the lesion, study eye acuity 20/100 or poorer, and fellow eye acuity at least 1 line better than that of the study eye. For more information, contact Theragenics at 877/960-1234.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
© 2025 MJH Life Sciences

All rights reserved.